GlassScriptPhysician profile
Laura J Haney
NPI 1114481140
$3,417.86
in general payments reported to CMS, 2019-2025
19 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $442 · 2022: $617 · 2023: $1,629 · 2024: $400 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,185 · Consulting Fee: $1,000 · Education: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,185.18 |
| Consulting Fee | $1,000.00 |
| Education | $173.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,000.00 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $465.21 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $397.75 | 2021-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $238.94 | 2021-2024 | Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $213.71 | 2021-2024 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $185.47 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $153.81 | 2021-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $133.42 | 2021-2025 | Aristada, Aristada Initio, Lybalvi |
| Corium, LLC | $124.48 | 2022-2025 | Azstarys |
| Abbvie INC. | $96.73 | 2021-2023 | |
| Lundbeck LLC | $89.01 | 2021-2023 | Rexulti |
| Axsome Therapeutics, INC. | $86.07 | 2023-2024 | Auvelity |
| Sunovion Pharmaceuticals INC. | $65.17 | 2022 | |
| Indivior INC. | $54.87 | 2022-2023 | Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $37.38 | 2021-2024 | Trintellix |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $26.67 | 2024 | |
| Ironshore Pharmaceuticals INC. | $18.61 | 2022 | |
| Novo Nordisk INC | $17.77 | 2021 | |
| Merck Sharp & Dohme LLC | $12.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Haney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.